Connect with us

Emerging Markets

Sunhydrogen Inc (OTCMKTS: HYSR) Running Northbound as Renewable Hydrogen Innovator Makes Significant Reversal off $0.026

Published

1 year ago

on

Sunhydrogen Inc (OTCMKTS: HYSR) is an exciting penny stock that is starting to get noticed again as it moves steadily northbound since reversing off $0.026 lows last week. HYSR is a stock with a long history of big moves starting in 2014 and continuing onward with the most recent run up in early 2021 to highs of $0.34 per share. So, when this one heats up, investors pay attention. HYSR also has an established shareholder base that will jump all over this one anytime in runs. 

While the stock was dropping over the past year from $0.34 highs in early 2021 the Company has made progress. They entered into agreements with two technology development partners; InRedox in Longmont, Colorado and SCHMID Group in Freudenstadt, Germany and together they successfully completed production of 100 demonstration units of its Gen 1 technology, alongside the research team at the University of Iowa. More recently HYSR has expanded its industrial partnerships across the U.S., Germany, South Korea and Japan, and has renewed and initiated new collaborations with the University of Iowa and the University of Michigan. HYSR plans to build on this progress with multiple production-quality prototype demonstrations by the end of the year. The Company also brought on Dr. Arthur J. Nozik, a distinguished leader in photoelectrochemistry, semiconductor nanoscience and additional closely related fields, as Scientific Adviser to the company. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Sunhydrogen Inc (OTCMKTS: HYSR) is developing a breakthrough, low-cost technology to make renewable hydrogen using sunlight and any source of water, including seawater and wastewater. The only byproduct of hydrogen fuel is pure water, unlike hydrocarbon fuels such as oil, coal and natural gas that release carbon dioxide and other contaminants into the atmosphere when used. By optimizing the science of water electrolysis at the nano-level, our low-cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, ultimately producing environmentally friendly renewable hydrogen. Using the Company’s low-cost method to produce renewable hydrogen, HYSR intends to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles.   

The SunHydrogen solution offers an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source of water. The Company’s core technology is a self-contained, nanoparticle-based hydrogen generator that mimics photosynthesis to split water molecules, resulting in hydrogen. By optimizing the science of water electrolysis at the nano-level, HYSR believes it has developed a low-cost method to potentially produce environmentally friendly renewable hydrogen. With a target cost of $2.50/kg., HYSR aspires for its technology to be cost-competitive with brown hydrogen and below the cost of clean hydrogen competitors.   

Powered by solar energy, billions of microscopic nanoparticles split apart water at the molecular level, extracting hydrogen for use as a clean energy source and leaving behind only clean oxygen as a byproduct. This process is similar to what happens inside a plant cell during photosynthesis: Each Photoelectrochemically Active Heterostructures (or PAH) nanoparticle is a microscopic machine, composed of multiple layers enabling the solar electrolysis reaction to take place.  

In 2021, the Company made strides toward the commercialization of its nanoparticle technology and entered into agreements with two technology development partners; InRedox in Longmont, Colorado and SCHMID Group in Freudenstadt, Germany. InRedox supported the design and production of essential materials for the Company’s nanoparticle technology while SCHMID worked to develop the process and equipment to manufacture and scale up the technology. The Company successfully completed production of 100 demonstration units of its Gen 1 technology. Both Schmid and InRedox work alongside the research team at the University of Iowa, a longtime technology development partner to SunHydrogen under sponsored research agreement.  

To Find out the inside Scoop on HYSR Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HYSR

The global hydrogen market is large and growing rapidly. Over 110 countries have set goals to achieve net-zero emissions by 2050, and as governments look to clean energy sources to help them meet their targets, hydrogen is emerging as a promising solution. It is estimated that nearly 25% of global energy will come from clean hydrogen alone by 2050 a tenfold increase from today, which could bring in a projected $2.5 trillion in annual revenues (Source: Bank of America Securities, New Energy Behind Green Hydrogen).  

HYSR has a growing intellectual property portfolio securing its first patent in 2017 covering the structural design of Photoelectrochemically Active Heterostructures (PAH) US Patent No. 9,593,053B1. In 2018 the Company was issued another patent covering the method for manufacturing PAH US Patent No. 9,593,053B2. Patents covering the Company’s semiconductor designs have been issued in Australia in April of 2018, China and Europe in March of 2019, and in the U.S. as United States Patent No. 10,100,415 in October of 2018. A patent application is currently pending in India.  On September 26, 2016, the Company filed jointly with the University of Iowa a provisional application for “Integrated Membrane Solar Fuel Production Assembly.” Also on September 26, 2017, HSYR filed a PCT Application that was later nationalized in the U.S. on March 26, 2019. The U.S. patent application for this important invention is pending and prosecution is ongoing.  

According to a progress report from earlier this year HYSR has expanded its industrial partnerships across the U.S., Germany, South Korea and Japan, and has renewed and initiated new collaborations with the University of Iowa and the University of Michigan, respectively.=  

SunHydrogen started 2022 with the addition of a new research and development laboratory in Coralville, Iowa, to fuel its goal of scaling up fabrication of its nanoparticle hydrogen generator units by the end of the 2022 fiscal year. The Company has hired several new senior engineers and chemists and are in the process of streamlining manufacturing operations, a task made more accessible by increasing our personnel. The Company plans to build on this progress in 2022 with multiple production-quality prototype demonstrations by the end of the year.  

On May 10 HYSR announced the appointment of Dr. Arthur J. Nozik, a distinguished leader in photoelectrochemistry, semiconductor nanoscience and additional closely related fields, as Scientific Adviser to the company. Prior to NREL, Dr. Nozik held research positions at the Allied Chemical Corporation and the American Cyanamid Company, where efforts were focused on bringing emerging technologies and solutions to commercialization. Dr. Nozik has published over 270 peer-reviewed papers, proceedings, books and book chapters. He has been cited over 47,000 times, presented over 380 invited talks and has been awarded 11 U.S. patents and numerous honors for his work. Additionally, Dr. Nozik serves as a bi-annual consultant for Samsung, evaluating proposals from external scientists in the fields of solar energy, quantum-computing, electronics and more to determine if they are scientifically sound and suitable for integration with Samsung.  

HYSR CEO Tim Young stated: “Dr. Nozik brings an immense wealth of knowledge to our team. It will be extremely valuable for him to not only evaluate our current methodology, but also bring new insights, strategies and solutions to our scientists. We are grateful for the opportunity to work with someone who has been at the cutting edge of this field since the start.” 

For more on HYSR Subscribe Right Now!

Currently trading at a $144 million market valuation HSYR has 4.2 billion out of 10 billion authorized shares outstanding. The Company is well funded moving forward with $42.6 million in the treasury and $7.4 million in marketable securities on $39.5 million in liabilities and the Company is pre revenue. HYSR is an exciting story developing in small caps addressing a booming hydrogen generation market size which was USD 142.33 billion in 2019 and is projected to reach USD 208.86 billion by 2027 and a trillion by 2050. At current levels the stock is at the bottom of its range and trading just over 52-week lows with significant catalysts coming in 2022. The stock has momentum, liquidity and legions of shareholders who will jump on this one anytime it moves. Microcapdaily covered HSYR in our article (Sunhydrogen Inc (OTCMKTS: HYSR) A Rising Bull) on July 29, 2020 when the stock was sub $0.01 just as it was taking off on its run to $0.34 highs in early 2021 and we will be updating on HSYR so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HYSR either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

5 days ago

on

May 31, 2023

By

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

2 weeks ago

on

May 21, 2023

By

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

3 weeks ago

on

May 14, 2023

By

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.